Who are Navelbine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dulcotil, Taxotere, Oncovin, Oncovin, VIN, VLI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vinorelbine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Navelbine — Competitive Intelligence Brief

Navelbine (vinorelbine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vinca Alkaloid. Area: Oncology.

marketed Vinca Alkaloid Substance-K receptor Oncology Live · refreshed every 30 min

Target snapshot

Navelbine (vinorelbine) — Pierre Fabre. Navelbine works by binding to the Substance-K receptor, disrupting microtubule formation and inhibiting cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Navelbine TARGET	vinorelbine	Pierre Fabre	marketed	Vinca Alkaloid	Substance-K receptor	1994-01-01
Dulcotil	SULOCTIDIL		marketed	suloctidil	Adenosine receptor A3, Substance-K receptor, 5-hydroxytryptamine receptor 1A	1979-01-01
Taxotere	Taxotere	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	marketed		Multidrug resistance-associated protein 7, Multidrug resistance protein 1, Substance-K receptor
Oncovin	Vincristine Sulfate	Pfizer Inc.	marketed	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Oncovin	vincristine	Pfizer Inc.	marketed	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
VIN	VIN	Italian Sarcoma Group	marketed	Vinca alkaloid; microtubule inhibitor	β-tubulin
VLI	VLI	Spectrum Pharmaceuticals, Inc	marketed	Vinca alkaloid	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vinca Alkaloid class)

Pfizer Inc. · 2 drugs in this class
Pierre Fabre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Navelbine — Competitive Intelligence Brief. https://druglandscape.com/ci/vinorelbine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab